Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bacci, G.
Right arrow Articles by Galletti, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bacci, G.
Right arrow Articles by Galletti, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1126-1134, 2003
© 2003 European Society for Medical Oncology

Original Paper

Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide

G. Bacci1,+, A. Briccoli2, M. Rocca2, S. Ferrari1, D. Donati3, A. Longhi1, F. Bertoni4, P. Bacchini4, S. Giacomini3, C. Forni1, M. Manfrini3 and S. Galletti5

1 Chemotherapy, 2 General Surgery, 3 Orthopaedic Surgery, 4 Pathology and 5 Ultrasonography, Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy

Received 19 November 2002; revised 4 February 2003; accepted 14 March 2003

Background:

Effective adjuvant or neoadjuvant regimens of chemotherapy have dramatically improved the prognosis of patients with high-grade osteosarcoma of the extremity, localized at diagnosis. Currently, little is known about patients with metastatic disease at presentation.

Patients and methods:

From May 1995 to May 2000, 57 patients with osteosarcoma of the extremity, metastatic at presentation, were treated according to the following scheme: primary chemotherapy, restaging, simultaneous resection of primary tumor and metastatic lesions, and maintenance chemotherapy.

Results:

Thirty-five patients achieved remission. At a follow-up ranging from 2 to 7 years, seven remained continuously free of disease, one died of chemotherapy-related toxicity and 27 patients relapsed. Twenty-one of the 22 patients who never achieved remission died as a result of the tumor, as well as 20 of the 27 who achieved remission but then relapsed. Of the remaining seven relapsing patients, six are alive with uncontrolled disease, while one is alive and free of disease 24 months after the last post-relapse treatment. Two-year event-free survival (EFS) and overall survival (OS) were 21% and 55%, respectively. These results are significantly poorer than those achieved in 128 contemporary patients with non-metastatic disease at presentation, treated with the same chemotherapy protocol (2-year EFS and OS of 75% and 94%, respectively).

Conclusions:

The results of our study confirm that the prognosis of patients with osteosarcoma of the extremity, metastatic at presentation, remains poor, despite the use of aggressive treatments.

Key words: limb salvage, lung metastases, metastasectomy, neoadjuvant chemotherapy, osteosarcoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
T.-a. Matsui, Y. Sowa, T. Yoshida, H. Murata, M. Horinaka, M. Wakada, R. Nakanishi, T. Sakabe, T. Kubo, and T. Sakai
Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells
Carcinogenesis, September 1, 2006; 27(9): 1768 - 1777.
[Abstract] [Full Text] [PDF]

Home page
 J Bone Joint Surg BrHome page
G. Bacci, N. Fabbri, A. Balladelli, C. Forni, E. Palmerini, and P. Picci
Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients
J Bone Joint Surg Br, August 1, 2006; 88-B(8): 1071 - 1075.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. S. Petrilli, B. de Camargo, V. O. Filho, P. Bruniera, A. L. Brunetto, R. Jesus-Garcia, O. P. Camargo, W. Pena, P. Pericles, A. Davi, et al.
Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: Prognostic Factors and Impact on Survival
J. Clin. Oncol., March 1, 2006; 24(7): 1161 - 1168.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Scotlandi, M. C. Manara, G. Nicoletti, P.-L. Lollini, S. Lukas, S. Benini, S. Croci, S. Perdichizzi, D. Zambelli, M. Serra, et al.
Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors
Cancer Res., May 1, 2005; 65(9): 3868 - 3876.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.